Al-Tayeb, Al-Noor OpiedAbubakr, Mohammed HayatiElrheima, Hafsa AhmedHabbani, Ahmed KhalidElrasul, Rami Y. Hassab2024-03-282024-03-282024-03European Journal of Clinical and Experimental Medicine T. 22, z. 1 (2024), s. 68–72https://repozytorium.ur.edu.pl/handle/item/10358The study was approved by the ethical committees of the University of Medical Sciences and Technology (IRB UMST/EG/2022/18, approval date 11/01/2022). Verbal consents were obtained from all participants, and approval was granted by the hospital administration through the office of the medical director.Introduction and aim. Methamphetamine-use disorder is a pressing global public health issue. In Sudan, the escalating meth amphetamine (METH) consumption has become a significant social and health problem. This study aims to evaluate liver and kidney biomarkers in methamphetamine addicts in Khartoum state Material and methods. The study was an analytical prospective cross-sectional hospital-based study. One hundred partici pants were enrolled in this study, fifty were cases (methamphetamine addicts), and others were healthy non-METH users as a comparative group. Results. METH users had a mean age of (27±7) years and had been using METH for an average of (14±9) months. Urea and cre atinine levels were also significantly elevated in METH users compared to non-users, with p<0.001 and p=0.044, respectively. Their aspartate transaminase (AST) and alanine transaminase (ALT) levels were significantly higher compared to non-users, with p<0.001. Conclusion. There was significant increases in creatinine, urea, and aminotransferases levels in the case group. ALT showed a moderate positive correlation with abuse duration, while AST showed no significant correlation. Urea and creatinine levels had strong and moderate positive correlations with abuse duration, respectively.engAttribution-NonCommercial-NoDerivs 3.0 Polandhttp://creativecommons.org/licenses/by-nc-nd/3.0/pl/aminotransferasescreatininemethamphetamineureaarticle10.15584/ejcem.2024.1.102544-1361